Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Bayer Pharma AG | 1,246 |
| 2 | Merck Sharp and Dohme LLC | 631 |
| 3 | AbbVie Inc | 630 |
| 4 | Merck Patent GmbH | 616 |
| 5 | Bayer Intellectual Property GmbH | 476 |
| 6 | Bayer AG | 410 |
| 7 | Vertex Pharmaceuticals Inc | 342 |
| 8 | Human Genome Sciences Inc | 217 |
| 9 | Incyte Corp | 202 |
| 10 | Organon Pharma UK Ltd | 188 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 12,810 |
| 2 | A61K | Medicinal preparations | 12,336 |
| 3 | C07D | Heterocyclic compounds | 7,954 |
| 4 | C07K | Peptides | 2,926 |
| 5 | C12N | Microorganisms, enzymes | 1,139 |
| 6 | G01N | Investigating / analysing materials | 992 |
| 7 | Y02A | Climate change adaptation | 774 |
| 8 | C07C | Acyclic and carbocyclic compounds | 686 |
| 9 | C07B | General methods of organic chemistry | 620 |
| 10 | C12Q | Measuring/testing involving enzymes | 541 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF | 2010 | Endo Pharmaceuticals Solutions Inc | 9 |
| Histrelin synthesizing method | 2013 | BINHAI GL PEPTIDE CO., LTD. | 3 |
| Method for synthesizing histrelin in full liquid phase | 2021 | Hunan Santai Pharmaceutical Co.,Ltd. | 1 |
| Method for specifically synthesizing histrelin | 2017 | Guo Tai bio tech ltd, Hefei | 1 |
| IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF | 2010 | Endo Pharmaceuticals Solutions Inc | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Hormonal and reproductive studies | 1 |
| 2 | Prostate Cancer Diagnosis and Treatment | 1 |
| 3 | Sperm and Testicular Function | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Amicur Farkas | Shaare Zedek Medical Center | 8 |
| 2 | Boris Chertin | Shaare Zedek Medical Center | 8 |
| 3 | C. Wayne Bardin | Population Council | 7 |
| 4 | Erica A. Eugster | Indiana University – Purdue University Indianapolis | 7 |
| 5 | Irving M. Spitz | Ben-Gurion University of the Negev | 7 |
| 6 | K. Sundaram | Population Council | 7 |
| 7 | David R. Meldrum | University of California, Los Angeles | 6 |
| 8 | John K.H. Lu | University of California, Los Angeles | 6 |
| 9 | Marcelle I. Cedars | University of California, Los Angeles | 6 |
| 10 | Howard L. Judd | University of California, Los Angeles | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-Releasing Hormone Agonist and Estrogen/Progestin* | 1991 | 159 | Menstrual Health and Disorders |
| Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. | 1987 | 133 | Endometriosis Research and Treatment |
| The Role of Gonadotropin-Releasing Hormone in Murine Preimplantation Embryonic Development* | 1999 | 114 | Reproductive Biology and Fertility |
| Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease* | 1987 | 96 | Reproductive Biology and Fertility |
| A Gonadotropin Releasing Hormone Analogue Prevents Cyclical Attacks of Porphyria | 1990 | 94 | Heme Oxygenase-1 and Carbon Monoxide |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Vantas?
Which patent assignees hold the most patents related to this compound's technology space?
What are the main therapeutic research areas associated with Vantas?
How many patents have been filed for histrelin delivery methods?
What are the dominant patent classification codes for compounds in this space?